Healthcare Services

Pediatric Brain Tumors Market Outlook 2026–2030: Key Business Drivers and Trends

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pediatric brain tumors market from 2026–2035 with trusted insights from The Business Research Company

How much is the Pediatric Brain Tumors Market valued at in 2026, and what valuation is forecast for 2030?

The market for pediatric brain tumors has experienced substantial growth in recent years. It is projected to expand from $1.4 billion in 2025 to $1.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.9%. The market’s historical development can be attributed to factors like limited awareness of pediatric brain tumors, a reliance on conventional therapies, minimal adoption of advanced imaging techniques, a scarcity of specialized pediatric neuro-oncology centers, and restricted access to targeted and immunotherapy treatments.

The market size for pediatric brain tumors is poised for significant expansion over the next few years, with projections indicating a rise to $1.93 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth throughout the forecast period stems from factors such as the increasing incidence of pediatric brain tumors, the growing adoption of precision medicine, the rising integration of artificial intelligence and digital imaging in diagnostics, an intensifying focus on personalized treatment plans, and increased funding for pediatric neuro-oncology research. Furthermore, major trends in this period include the wider acceptance of precision medicine for pediatric brain tumors, the expanding integration of digital imaging and AI-based diagnostics, the greater utilization of targeted therapies and immunotherapies, an increased emphasis on minimally invasive surgical techniques, and escalating investment in pediatric neuro-oncology research.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21248&type=smp

What Drivers Are Influencing The Growth Of The Pediatric Brain Tumors Market?

The escalating need for personalized medicine is anticipated to fuel the expansion of the pediatric brain tumors market. This healthcare strategy involves customizing treatments and medical decisions based on an individual’s genetic makeup, lifestyle, and specific health requirements. The surge in demand for personalized medicine is attributed to advancements in genetic research, improved diagnostic tools, and the promise of more effective and targeted treatments. By tailoring therapies to a child’s unique tumor type, mutation, and response, personalized medicine enables highly effective targeted interventions that minimize damage to healthy tissue, thereby enhancing outcomes and reducing side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, stated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, significantly up from six in 2022. Thus, the increasing demand for personalized medicine is a primary factor propelling the growth of the pediatric brain tumor market.

What Segments Are Included Within The Pediatric Brain Tumors Market?

The pediatric brain tumors market covered in this report is segmented –

1) By Type: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma Or Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors

2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy

3) By Diagnosis Method: Imaging Techniques, Biopsy, Neurological Exam, Lumbar Puncture

4) By Age Group: Infants, Toddlers, Children, Adolescents

5) By Application: Hospitals And Clinics, Medical Research Centers, Academic Institutes, Other Applications

Subsegments:

1) By Gliomas: Low-Grade Gliomas, High-Grade Gliomas

2) By Mixed Neuronal-Glial Tumors: Gangliogliomas, Dysembryoplastic Neuroepithelial Tumors (DNET)

3) By Embryonal Tumors: Medulloblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Primitive Neuroectodermal Tumors (PNET)

4) By Choroid Plexus Papilloma Or Carcinoma: Choroid Plexus Papilloma, Choroid Plexus Carcinoma

5) By Tumors Arising From Non-Neuroepithelial Tissue: Rhabdomyosarcoma, Ewing’s Sarcoma

6) By Meningeal Tumors: Meningiomas, Hemangiopericytomas

What Trends Are Driving The Growth Trajectory Of The Pediatric Brain Tumors Market?

Leading companies within the pediatric brain tumors market are prioritizing the development of advanced therapies, such as Type II RAF inhibitors, to enhance targeted treatments and improve patient outcomes. Type II RAF inhibitors function as targeted therapies by concentrating on the suppression of RAF kinases, especially those with mutations that drive tumor proliferation. These inhibitors are engineered to pinpoint abnormal RAF protein structures found in specific subtypes of pediatric low-grade glioma (pLGG), effectively disrupting the faulty signaling pathways that contribute to tumor cell growth and survival. For instance, in April 2024, Day One Biopharmaceuticals, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for OJEMDA (tovorafenib) for treating relapsed or refractory pediatric low-grade glioma (pLGG) in patients aged 6 months and older with specific BRAF alterations. This approval establishes OJEMDA as the first FDA-approved therapy designed to target BRAF fusions or mutations in this particular patient demographic. The approval is substantiated by an overall response rate of 51% reported from the FIREFLY-1 clinical trial, which evaluated the drug’s effectiveness for this condition. It is specifically intended for children with brain tumors that have not responded to prior treatments.

Who Are The Major Companies Operating In The Pediatric Brain Tumors Market?

Major companies operating in the pediatric brain tumors market are Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Novocure, Blueprint Medicines, Oncoheroes Biosciences, Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children’s Therapeutics, Pfizer Inc., Merck & Co Inc., Bristol Myers Squibb Company, Sanofi, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Day One Biopharmaceuticals Inc., Biodexa Pharmaceuticals, Cellectar Biosciences Inc., ZIOPHARM Oncology Inc., Y-mAbs Therapeutics Inc., Neonc Technologies Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Pediatric Brain Tumors Market?

North America was the largest region in the pediatric brain tumors market in 2025. The regions covered in the pediatric brain tumors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pediatric Brain Tumors Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21248&type=smp

Browse Through More Reports Similar to the Global Pediatric Brain Tumors Market 2026, By The Business Research Company

Paraganglioma Market Report 2026

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Pediatric Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795